2026-10-12T12:23:04Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33872224 2026-09-17T05:57:06Z category_696 portal_316 item_type_3 month_year_09_2026

Data Sheet 1_Neurological and hematological safety profiles of GSK-3β inhibitors: insights from multi-database pharmacovigilance and experimental validation.zip Xinchi Luan (22444384) Bingcheng Fan (18105966) Xuezhe Wang (17732096) Xiaoxuan Li (4488253) Yuhui Song (16379270) Xiaolei Zhang (316541) Huhu Zhang (17618578) Ruolan Chen (12234265) Yi Li (1144) Zelin Yang (7915037) Ning Liu (168279) Weiwei Qi (591190) Wensheng Qiu (497921) Jing Guo (102972) Genetic Immunology adverse drug reactions bibliometrics cancer disproportionality analysis GSK-3β inhibitors Background<p>Glycogen synthase kinase 3 beta (GSK-3β) inhibitors have received substantial attention for their therapeutic potential; however, their systemic safety profile remains incompletely characterized.</p>Objective<p>This study characterized the research landscape and exploratory safety-reporting signals associated with agents with reported GSK-3β activity by integrating bibliometric analysis, pharmacovigilance, and preliminary experimental assessment.</p>Methods<p>A multi-layered framework included bibliometric analysis, disproportionality analyses of FAERS, JADER, and CVARD reports, and transcriptomic profiling. SH-SY5Y cells were treated with 9-ING-41 (1 μM, 24 h); cell viability, qRT-PCR, and DCFH-DA-based intracellular oxidative-stress measurements were assessed.</p>Results<p>Bibliometric analysis showed sustained growth in GSK-3β-related research. Pharmacovigilance identified neurological and hematologic disproportionality signals across 27 System Organ Classes. In SH-SY5Y cells, 9-ING-41 was associated with modest changes in neuronal-function, inflammatory-response, and GSK-3β/Wnt-pathway transcripts, increased DCFH-DA fluorescence, and high cell viability. These cell-based observations are preliminary and do not establish clinical causality.</p>Conclusion<p>The literature-derived study-drug panel showed exploratory neurological and hematologic reporting signals. Cross-database recurrence can prioritize hypotheses, whereas pharmacological heterogeneity and the limitations of spontaneous reporting require cautious interpretation. The SH-SY5Y experiments provide preliminary biological plausibility only.</p> 2026-09-17T05:57:06Z Dataset Dataset 10.3389/fimmu.2026.1915614.s001 https://figshare.com/articles/dataset/Data_Sheet_1_Neurological_and_hematological_safety_profiles_of_GSK-3_inhibitors_insights_from_multi-database_pharmacovigilance_and_experimental_validation_zip/33872224 CC BY 4.0